Furthermore, as firms like Genentech (now Roche; Basel), Imclone (now Eli Lilly, Indianapolis ... both incremental funding and 'big pharma' validation. For example, the Novartis Option Fund ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...

With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas, providing cutting-edge solutions in oncology, diabetes, immunology, and neuroscience. The Indianapolis ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...

Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular drugs.

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

INDIANAPOLIS (WISH) – The FDA has now approved Lilly’s Zepbound (glp-1 agonist) for sleep apnea. It’s the first medication approved for this condition. Sleep apnea affects 25 million ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday, Lilly’s dual ...

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens ... Shares of the Indianapolis-based drugmaker were up 1.14% in after-market trading ...